Please enable JavaScript to continue using this application.

Compare $FATE vs $UPB | Chartloom

Compare

$FATE vs $UPB

Fate Therapeutics Inc · Upstream Bio Inc

FATE

Fate Therapeutics Inc

UPB

Upstream Bio Inc

Compare $FATE vs $UPB

Comparing Fate Therapeutics Inc and Upstream Bio Inc

FATEFate Therapeutics Inc

UPBUpstream Bio Inc

FATEFate Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

54.34x

Rev growth (TTM)

-23.4%

YTD performance

120.2%

52W performance

44.4%

FCF yield

-41.6%

UPBUpstream Bio Inc

Market cap

$256M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

168.72x

Rev growth (TTM)

16.0%

YTD performance

-82.6%

52W performance

-75.2%

FCF yield

-53.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FATE

UPB

Detailed metrics comparison

FATE

Fate Therapeutics Inc

UPB

Upstream Bio Inc

Market Cap

FATE$254M

UPB$256M

Enterprise Value

FATE$234M

UPB$176M

Price

FATE$2.18

UPB$4.70

P/E Ratio

FATEN/A

UPBN/A

P/S Ratio

FATE39.15x

UPB80.99x

EV/Sales

FATE35.98x

UPB55.85x

EV/EBITDA

FATE0.00x

UPB0.00x

P/B Ratio

FATE1.81x

UPB1.02x

P/FCF Ratio

FATEN/A

UPBN/A

EV/FCF

FATE-2.21x

UPB-1.29x

PEG Ratio

FATEN/A

UPBN/A

Forward P/E (NTM)

FATEN/A

UPBN/A

Forward P/S (NTM)

FATE54.34x

UPB168.72x

Revenue (TTM)

FATE$6M

UPB$3M

Revenue Growth (YoY)

FATE-23.4%

UPB16.0%

Forward Rev Growth

FATE-17.6%

UPB-48.7%

Gross Margin (TTM)

FATE0.0%

UPB0.0%

Operating Margin (TTM)

FATE0.0%

UPB0.0%

EBITDA Margin (TTM)

FATE-1873.4%

UPB-5376.3%

Net Margin (TTM)

FATE-1941.1%

UPB-4955.7%

FCF Margin (TTM)

FATE-1627.8%

UPB-4321.2%

Net Income (TTM)

FATE$-126M

UPB$-157M

FCF (TTM)

FATE$-106M

UPB$-136M

EPS (TTM)

FATE-$1.05

UPB-$2.87

ROE (TTM)

FATE-6508.0%

UPB-4840.0%

ROA (TTM)

FATE-4173.0%

UPB-4657.0%

ROIC (TTM)

FATE-6174.0%

UPB-4840.0%

Cash

FATE$32M

UPB$79M

Debt

FATE$12M

UPB$0

Net Cash/Debt

FATE$21M

UPB$79M

Current Ratio (TTM)

FATE4.85x

UPB27.99x

Quick Ratio (TTM)

FATE4.74x

UPB27.84x

Debt/Equity (TTM)

FATE0.08x

UPB0.00x

Debt/Assets (TTM)

FATE0.0%

UPB0.0%

Interest Coverage (TTM)

FATEN/A

UPBN/A

Net Debt/EBITDA (TTM)

FATE0.00x

UPB0.00x

Beta

FATE2.67

UPB2.30

52W Performance

FATE44.4%

UPB-75.2%

YTD Performance

FATE120.2%

UPB-82.6%

% from 52W High

FATE-32.5%

UPB-86.0%

% from 52W Low

FATE129.5%

UPB7.7%

Asset Turnover (TTM)

FATE0.02x

UPB0.01x

FCF Yield (TTM)

FATE-41.6%

UPB-53.4%

Earnings Yield (TTM)

FATE-49.6%

UPB-61.2%

Dividend Yield (TTM)

FATEN/A

UPBN/A

Rule of 40

FATE-1,651.1

UPB-4,305.2

EV/GP/RG

FATEN/A

UPBN/A

Ticker research

View FATE research View UPB research

Metric	FATE Fate Therapeutics Inc	UPB Upstream Bio Inc
Market & Valuation
Market Cap	$254M	$256M
Enterprise Value	$234M	$176M
Price	$2.18	$4.70
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	80.99x
EV/Sales	35.98x	55.85x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-1.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	168.72x
Revenue & Growth
Revenue (TTM)	$6M	$3M
Revenue Growth (YoY)	-23.4%	16.0%
Forward Rev Growth	-17.6%	-48.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	-5376.3%
Net Margin (TTM)	-1941.1%	-4955.7%
FCF Margin (TTM)	-1627.8%	-4321.2%
Net Income (TTM)	$-126M	$-157M
FCF (TTM)	$-106M	$-136M
EPS (TTM)	-$1.05	-$2.87
ROE (TTM)	-6508.0%	-4840.0%
ROA (TTM)	-4173.0%	-4657.0%
ROIC (TTM)	-6174.0%	-4840.0%
Financial Health
Cash	$32M	$79M
Debt	$12M	$0
Net Cash/Debt	$21M	$79M
Current Ratio (TTM)	4.85x	27.99x
Quick Ratio (TTM)	4.74x	27.84x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	2.30
52W Performance	44.4%	-75.2%
YTD Performance	120.2%	-82.6%
% from 52W High	-32.5%	-86.0%
% from 52W Low	129.5%	7.7%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.01x
FCF Yield (TTM)	-41.6%	-53.4%
Earnings Yield (TTM)	-49.6%	-61.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	-4,305.2
EV/GP/RG	N/A	N/A
Ticker research	View FATE research	View UPB research

Valuation

P/S Ratio

FATE

39.15x

UPB

80.99x

EV/FCF

FATE

-2.21x

UPB

-1.29x

Growth & revenue

Revenue Growth TTM

UPB

16.0%

FATE

-23.4%

Forward Revenue Growth

FATE

-17.6%

UPB

-48.7%

Profitability & performance

Gross Margin

FATE

0.0%

UPB

0.0%

ROE

UPB

-4840.0%

FATE

-6508.0%

FCF Yield %

FATE

-41.6%

UPB

-53.4%

52-Week Performance

FATE

44.4%

UPB

-75.2%

Detailed metrics comparison

FATE

Fate Therapeutics Inc

UPB

Upstream Bio Inc

Market Cap

FATE$254M

UPB$256M

Enterprise Value

FATE$234M

UPB$176M

Price

FATE$2.18

UPB$4.70

P/E Ratio

FATEN/A

UPBN/A

P/S Ratio

FATE39.15x

UPB80.99x

EV/Sales

FATE35.98x

UPB55.85x

EV/EBITDA

FATE0.00x

UPB0.00x

P/B Ratio

FATE1.81x

UPB1.02x

P/FCF Ratio

FATEN/A

UPBN/A

EV/FCF

FATE-2.21x

UPB-1.29x

PEG Ratio

FATEN/A

UPBN/A

Forward P/E (NTM)

FATEN/A

UPBN/A

Forward P/S (NTM)

FATE54.34x

UPB168.72x

Revenue (TTM)

FATE$6M

UPB$3M

Revenue Growth (YoY)

FATE-23.4%

UPB16.0%

Forward Rev Growth

FATE-17.6%

UPB-48.7%

Gross Margin (TTM)

FATE0.0%

UPB0.0%

Operating Margin (TTM)

FATE0.0%

UPB0.0%

EBITDA Margin (TTM)

FATE-1873.4%

UPB-5376.3%

Net Margin (TTM)

FATE-1941.1%

UPB-4955.7%

FCF Margin (TTM)

FATE-1627.8%

UPB-4321.2%

Net Income (TTM)

FATE$-126M

UPB$-157M

FCF (TTM)

FATE$-106M

UPB$-136M

EPS (TTM)

FATE-$1.05

UPB-$2.87

ROE (TTM)

FATE-6508.0%

UPB-4840.0%

ROA (TTM)

FATE-4173.0%

UPB-4657.0%

ROIC (TTM)

FATE-6174.0%

UPB-4840.0%

Cash

FATE$32M

UPB$79M

Debt

FATE$12M

UPB$0

Net Cash/Debt

FATE$21M

UPB$79M

Current Ratio (TTM)

FATE4.85x

UPB27.99x

Quick Ratio (TTM)

FATE4.74x

UPB27.84x

Debt/Equity (TTM)

FATE0.08x

UPB0.00x

Debt/Assets (TTM)

FATE0.0%

UPB0.0%

Interest Coverage (TTM)

FATEN/A

UPBN/A

Net Debt/EBITDA (TTM)

FATE0.00x

UPB0.00x

Beta

FATE2.67

UPB2.30

52W Performance

FATE44.4%

UPB-75.2%

YTD Performance

FATE120.2%

UPB-82.6%

% from 52W High

FATE-32.5%

UPB-86.0%

% from 52W Low

FATE129.5%

UPB7.7%

Asset Turnover (TTM)

FATE0.02x

UPB0.01x

FCF Yield (TTM)

FATE-41.6%

UPB-53.4%

Earnings Yield (TTM)

FATE-49.6%

UPB-61.2%

Dividend Yield (TTM)

FATEN/A

UPBN/A

Rule of 40

FATE-1,651.1

UPB-4,305.2

EV/GP/RG

FATEN/A

UPBN/A

Ticker research

View FATE research View UPB research

Metric	FATE Fate Therapeutics Inc	UPB Upstream Bio Inc
Market & Valuation
Market Cap	$254M	$256M
Enterprise Value	$234M	$176M
Price	$2.18	$4.70
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	80.99x
EV/Sales	35.98x	55.85x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-1.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	168.72x
Revenue & Growth
Revenue (TTM)	$6M	$3M
Revenue Growth (YoY)	-23.4%	16.0%
Forward Rev Growth	-17.6%	-48.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	-5376.3%
Net Margin (TTM)	-1941.1%	-4955.7%
FCF Margin (TTM)	-1627.8%	-4321.2%
Net Income (TTM)	$-126M	$-157M
FCF (TTM)	$-106M	$-136M
EPS (TTM)	-$1.05	-$2.87
ROE (TTM)	-6508.0%	-4840.0%
ROA (TTM)	-4173.0%	-4657.0%
ROIC (TTM)	-6174.0%	-4840.0%
Financial Health
Cash	$32M	$79M
Debt	$12M	$0
Net Cash/Debt	$21M	$79M
Current Ratio (TTM)	4.85x	27.99x
Quick Ratio (TTM)	4.74x	27.84x
Debt/Equity (TTM)	0.08x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	2.30
52W Performance	44.4%	-75.2%
YTD Performance	120.2%	-82.6%
% from 52W High	-32.5%	-86.0%
% from 52W Low	129.5%	7.7%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.01x
FCF Yield (TTM)	-41.6%	-53.4%
Earnings Yield (TTM)	-49.6%	-61.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	-4,305.2
EV/GP/RG	N/A	N/A
Ticker research	View FATE research	View UPB research